Monday, August 27, 2007 7:43:12 AM
Princeton, N.J., Aug. 27 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today that the company will assist the World Health Organization's Special Program for Research and Training in Tropical Diseases (WHO/TDR) in its efforts to develop novel antimalarial agents. Pharmacopeia will receive funding to conduct medicinal chemistry research on compounds identified through WHO/TDR's drug screening program involving a network of centers in developed and developing countries. The goal of this project is to identify new lead series with the potential to become novel malaria drug candidates. Malaria kills more than one million people a year, with most of those being children in the developing world.
For more information about Pharmacopeia, please visit
http://www.pharmacopeia.com.
Contact:
Amy Sharpless
609-452-3643
ir_pr@pcop.com
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM